immunotherapy

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig...

FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma

Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patientsFirst Breakthrough Therapy Designation (BTD) for daretabart,...

Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership

COM002 is a first-in-class complement-powered immune engager based on Commit Biologics’ proprietary BiCE™ platform.Anne-Marie Levy Rasmussen appointed Chief Operating Officer...

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistance Study...

Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access

John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at...

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

error: Content is protected !!